title: Apoptotic effects of dipyrido [3,2-a:2',3'-c] phenazine (dppz) Au(III) complex against diethylnitrosamine/phenobarbital induced experimental hepatocarcinogenesis in rats.
abstract: We evaluated the effects of dipyrido [3,2-a:2',3'-c] phenazine (dppz) Au(III) complex ([Au(dppz)Cl2]Cl) on apoptosis during chemically induced hepatocellular carcinoma. 48 male Spraque-Dawley rats were divided into six groups; group I (control), group II [Dimethyl sulfoxide (DMSO)], group III ([Au(dppz)Cl2]Cl), group IV [diethylnitrosamine + Phenobabital (DEN + PB)], group V (DEN + PB + [Au(dppz)Cl2]Cl (2nd week)), and group VI (DEN + PB + [Au(dppz)Cl2]Cl (7th week). The rats in groups IV through VI were administrated with DEN in a single dose of intraperitoneal 175 mg/kg. After 2 weeks of DEN administration, these groups of rats were given daily PB in a dose of 500 ppm. In group V, after two weeks of DEN administration, [Au(dppz)Cl2]Cl complex (2 mg/kg) was given once a week by intraperitoneal injection. In the group VI, the rats were given a dose of 2 mg/kg [Au(dppz)Cl2]Cl complex once a week, 7 weeks after DEN administration. At the end of the study, blood and tissue samples were collected from the rats to determine levels of serum AST, ALT, and LDH, and caspase 3, p53, Bax, Bcl-2 and DNA fragmentation in liver. AST, ALT, LDH, and Bcl-2 levels were higher in group IV, compared to group I, but caspase 3 and p53 levels were lower. In group V, caspase 3, p53, Bax, and DNA fragmentation levels were higher than those of group IV. Caspase 3 and p53 levels increased in group VI compared with group IV. In conclusion, [Au(dppz)Cl2]Cl complex induced apoptosis by elevating levels of caspase 3, p53, Bax, and DNA fragmentation.
authors.affiliation: Department of Chemistry, Biochemistry Division, Faculty of Arts and Science, Aksaray University, Aksaray, Turkey, neslihan_tekin@hotmail.com.
authors.forename: Neslihan
authors.initials: N
authors.lastname: Tekin
authors.forename: Mehmet C
authors.initials: MC
authors.lastname: Ustuner
authors.forename: Fahrettin
authors.initials: F
authors.lastname: Akyuz
authors.forename: Cansu S
authors.initials: CS
authors.lastname: Ozbayer
authors.forename: Ozlem
authors.initials: O
authors.lastname: Aydın
authors.forename: Kadriye
authors.initials: K
authors.lastname: Benkli
authors.forename: Dilek
authors.initials: D
authors.lastname: Burukoglu
authors.forename: Irfan
authors.initials: I
authors.lastname: Degirmenci
authors.forename: Hilmi
authors.initials: H
authors.lastname: Ozden
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D053938:DNA Fragmentation / Q000187:drug effects; D004052:Diethylnitrosamine / Q000633:toxicity*; D006046:Gold / Q000737:chemistry; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D010619:Phenazines / Q000138:chemical synthesis / Q000494:pharmacology*; D010634:Phenobarbital / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D023382:Toxicity Tests, Acute
chemical_list: D000970:Antineoplastic Agents; D010619:Phenazines; C443808:dipyrido(3,2-a-2',3'-c)phenazine; D004052:Diethylnitrosamine; D006046:Gold; D010634:Phenobarbital
references.citation: Inorg Chem. 2006 Jan 9;45(1):230-5
references.pmid: 16390060
references.citation: Toxicol Pathol. 2007 Jun;35(4):495-516
references.pmid: 17562483
references.citation: Chem Biol Interact. 2009 May 15;179(2-3):131-44
references.pmid: 19073162
references.citation: J Clin Pathol. 2005 Feb;58(2):159-65
references.pmid: 15677536
references.citation: Life Sci. 2007 Jul 19;81(6):489-99
references.pmid: 17651763
references.citation: Life Sci. 2004 Sep 24;75(19):2303-16
references.pmid: 15350828
references.citation: Toxicol Appl Pharmacol. 2009 Jul 1;238(1):71-9
references.pmid: 19409407
references.citation: Mol Cancer. 2014 Mar 13;13:57
references.pmid: 24625085
references.citation: J Vet Sci. 2001 Apr;2(1):53-8
references.pmid: 14614295
references.citation: J Inorg Biochem. 2008 Mar;102(3):564-75
references.pmid: 18177942
references.citation: J Med Chem. 2006 Mar 9;49(5):1648-57
references.pmid: 16509581
references.citation: Cancer Res. 2006 Nov 1;66(21):10478-86
references.pmid: 17079469
references.citation: Anticancer Drugs. 2007 Mar;18(3):323-32
references.pmid: 17264766
references.citation: J Inorg Biochem. 2007 Jan;101(1):180-6
references.pmid: 17084460
references.citation: Hepatology. 2013 Feb;57(2):625-36
references.pmid: 22991197
references.citation: Int J Cancer. 2006 Mar 15;118(6):1527-38
references.pmid: 16206274
references.citation: PLoS One. 2013 Jul 24;8(7):e68710
references.pmid: 23894334
references.citation: Chem Biol Interact. 2013 Nov 25;206(2):214-21
references.pmid: 24060683
references.citation: Curr Pharm Des. 2010 Jun;16(16):1813-25
references.pmid: 20337575
references.citation: J Med Chem. 2005 Mar 10;48(5):1588-95
references.pmid: 15743200
references.citation: Chem Commun (Camb). 2005 Oct 14;(38):4764-76
references.pmid: 16193110
references.citation: J Biol Inorg Chem. 2010 May;15(4):573-82
references.pmid: 20112036
references.citation: J Inorg Biochem. 2011 Oct;105(10):1306-13
references.pmid: 21864808
references.citation: Curr Opin Chem Biol. 2003 Aug;7(4):481-9
references.pmid: 12941423
references.citation: Curr Pharm Des. 2009;15(7):777-91
references.pmid: 19275642
references.citation: J Biol Chem. 2000 Dec 8;275(49):38905-11
references.pmid: 10988287
references.citation: Cancer Sci. 2010 May;101(5):1314-9
references.pmid: 20345480
references.citation: Endocr Regul. 2001 Mar;35(1):53-9
references.pmid: 11308997
references.citation: Inorg Chem. 2005 Mar 21;44(6):1867-81
references.pmid: 15762713
references.citation: BMC Pharmacol. 2005 Oct 15;5:15
references.pmid: 16225695
references.citation: Cancer Res. 1999 Jul 1;59(13):3077-83
references.pmid: 10397248
references.citation: Epilepsia. 2005 Feb;46(2):217-23
references.pmid: 15679502
references.citation: Anticancer Res. 2007 Mar-Apr;27(2):965-71
references.pmid: 17465228
references.citation: Mod Pathol. 2004 Jul;17(7):861-7
references.pmid: 15098015
references.citation: Saudi Med J. 2008 Sep;29(9):1241-6
references.pmid: 18813404
references.citation: Exp Oncol. 2007 Mar;29(1):39-44
references.pmid: 17431387
references.citation: J Med Chem. 2002 Apr 11;45(8):1672-7
references.pmid: 11931621
references.citation: Chemotherapy. 2012;58(5):381-6
references.pmid: 23257706
references.citation: Cancer Cell Int. 2007 Apr 03;7:4
references.pmid: 17407577
references.citation: Neoplasia. 2005 Jan;7(1):24-36
references.pmid: 15720815
references.citation: J Inorg Biochem. 2012 Jan;106(1):32-42
references.pmid: 22112837
references.citation: Apoptosis. 2007 Feb;12(2):387-93
references.pmid: 17191126
references.citation: Molecules. 2013 Jun 19;18(6):7179-93
references.pmid: 23783456
references.citation: J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:213-9
references.pmid: 21199533
references.citation: Asian Pac J Cancer Prev. 2011;12(8):1925-9
references.pmid: 22292626
references.citation: J Biol Inorg Chem. 2006 Sep;11(6):745-52
references.pmid: 16763798
references.citation: Cell Prolif. 2009 Apr;42(2):229-40
references.pmid: 19317806
references.citation: Cancer. 2009 Oct 1;115(19):4459-69
references.pmid: 19572413
references.citation: Int J Nanomedicine. 2011;6:1889-901
references.pmid: 21931484